Compare Merck & Co., Inc. (MRK) vs Western Digital Corp (WDC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs Western Digital Corp — how do they compare? Merck & Co., Inc. trades at $148.1 (market cap $366.28B), while Western Digital Corp trades at $481 (market cap $172.09B). The key difference: Merck & Co., Inc. is far larger — about 2.1× Western Digital Corp's market cap, and Merck & Co., Inc. pays the higher dividend (2.29%). Which is the better fit depends on your goals.
| MRK | WDC | |
|---|---|---|
Market Cap | $366.28B | $172.09B |
Sector | Health | Technology |
52-Week High | $156.43 | $746.23 |
52-Week Low | $77.60 | $95.03 |
Enterprise Value | $413.04B | $171.56B |
Dividend Yield | 2.29% | 0.13% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Merck (MRK) trades at $148.49, down 1.23% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $156.71. The company reported strong earnings beats in recent quarters, with Q3 2026 results pending, and maintains a robust gross profit margin of 72.97%. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, reflecting strategic growth initiatives amid a competitive pharmaceutical landscape.
The outlook for MRK is positive, driven by earnings momentum and strategic acquisitions, but risks include high valuation multiples like a P/E of 118.77 and regulatory pressures. Investors should weigh the company's solid cash flow and analyst support against potential market volatility and integration challenges from recent M&A activity.
Western Digital (WDC) trades at $477.30, up 2.1% today, reflecting strong momentum amid AI-driven storage demand. The stock shows bullish technical signals, with recent earnings beats and a consensus analyst price target of $676.70 suggesting 42% upside. Fundamentals are robust, with a net income margin of 71.97% in 2025 and positive cash flow trends, though revenue declined to $9.52B from prior years.
Outlook remains positive due to AI data growth catalysts and shareholder returns, but risks include competitive pressures and volatility from high expectations. The stock's valuation multiples like P/E of 17.73 appear reasonable given growth prospects, supporting a bullish bias with caution on execution risks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About Western Digital Corp
Western Digital is a vertically integrated supplier of data storage solutions, spanning both hard disk drives and solid-state drives. In the HDD market it forms a practical duopoly with Seagate, and it is the largest global producer of NAND flash chips for SSDs in a joint venture with competitor Kioxia.
Read more on WDC →
